Welcome to our dedicated page for BillionToOne SEC filings (Ticker: BLLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for BillionToOne, Inc. (NASDAQ: BLLN), a Menlo Park, California-based molecular diagnostics company. BillionToOne focuses on prenatal and oncology testing built on its patented Quantitative Counting Templates (QCT) molecular counting platform, and its regulatory filings offer additional detail on its business, risks, and financial profile.
In registration statements and related prospectus materials filed in connection with its initial public offering on the Nasdaq Global Select Market, the company describes its mission to create powerful and accurate tests that are accessible to all. These filings discuss the role of the QCT platform, which BillionToOne characterizes as the only multiplex technology that can accurately count DNA molecules at the single-molecule level, and outline how this technology supports products such as the UNITY Complete non-invasive prenatal test and Northstar liquid biopsy assays.
Over time, investors can expect BillionToOne’s SEC filings to include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, along with any registration statements or proxy materials the company submits. These documents typically provide information on revenue sources across prenatal clinical testing, oncology clinical testing, and other services, as well as details on operating expenses, liquidity, and risk factors, as reflected in the company’s public financial communications and prospectus.
On Stock Titan, SEC filings for BLLN are supplemented with AI-powered summaries that explain key sections in plain language. Real-time updates from EDGAR help surface new filings as they become available, while AI-generated highlights can draw attention to topics such as segment performance, capital structure, and material events disclosed by BillionToOne in its official documents.
BillionToOne, Inc. investor David Tsao has disclosed a 6.9% beneficial ownership stake in the company’s Class A common stock as of 12/31/2025. This totals 3,035,767 shares over which he has sole voting and dispositive power.
The position consists of 1,000 Class A shares, 2,325,108 Class B shares that are convertible into Class A, and 709,659 Class A shares underlying stock options exercisable within 60 days. An additional 431,892 option shares that are not exercisable within 60 days are specifically excluded from this calculation.
Oguzhan Atay filed a Schedule 13G reporting a significant ownership position in BillionToOne, Inc. He is deemed to beneficially own 3,206,861 shares of Class A common stock, representing 7.3% of the class. This total includes Class B shares convertible into Class A, stock options exercisable within 60 days, and shares held by his spouse, over which he disclaims beneficial ownership.
BillionToOne, Inc. received a Schedule 13G reporting that venture investor NeoTribe-related funds and managing member Krishna Kittu Kolluri together beneficially own a significant stake in the company’s Class A common stock.
The filing shows NTV I holding 2,710,286 shares (6.6%), NTIF I holding 1,297,799 shares (3.1%), and NT SPV I holding 242,216 shares (0.6%), among other related entities. Aggregating these positions, Kolluri is reported to beneficially own 4,359,505 shares, representing 10.6% of the Class A common stock, with sole voting and dispositive power reported through various NeoTribe general partner and managing member roles. All ownership percentages are based on 41,216,110 shares of Class A common stock outstanding as of December 5, 2025, as stated in the company’s Form 10-Q.
Hummingbird-affiliated investors have disclosed a significant stake in BillionToOne’s Class A common stock. A group of Belgian investment funds and their managing entities, together with individuals Firat Ileri, Barend Van den Brande and Lukas Decoster, report beneficial ownership of 7,887,237 shares, representing 19.6% of BillionToOne’s Class A common stock, based on 40,167,729 shares outstanding as of November 6, 2025.
The stake was built primarily through purchases of multiple series of redeemable convertible preferred stock between 2019 and 2024, plus common shares, for a total purchase price of $93,673,956.50. Those preferred shares converted into Class A common stock on a one-for-one basis immediately before BillionToOne’s initial public offering.
The reporting persons state that the shares were acquired for investment purposes. They indicate they may from time to time buy more, hold, or sell shares, and may communicate with BillionToOne’s management, board members, and other shareholders about strategy, operations, and financing alternatives. Firat Ileri also serves as a director of BillionToOne.
BillionToOne, Inc. (BLLN) insiders reported a large structural change in their holdings tied to the company’s initial public offering. Investment entities affiliated with Hummingbird funds and HB&Q NV converted multiple series of preferred stock into common stock on a one-for-one basis automatically immediately prior to the closing of BillionToOne’s IPO of Class A common stock, without any cash changing hands.
Immediately before the IPO, each share of common stock was then automatically reclassified into one share of Class A common stock under a Rule 16b-7–exempt reclassification. After these steps, the Hummingbird-affiliated entities reported Class A common stock positions, including 2,631,664 shares and 2,580,833 shares for certain funds. Humming Bird Ventures Management NV may be deemed to beneficially own shares held by the Hummingbird funds, while its partners, including Firat Ileri, Barend Van den Brande, and Lukas Decoster, disclaim beneficial ownership beyond their economic interests.
BillionToOne, Inc. filed an initial ownership report showing that several Hummingbird investment vehicles are 10% owners as of
BillionToOne, Inc. filed a current report stating that it issued a press release on January 12, 2026, reiterating its guidance for the full year ended December 31, 2025 and initiating guidance for full year 2026. This means the company confirmed its prior outlook for 2025 while also providing its initial expectations for 2026.
The company also noted that the investor presentation used at the 2026 J.P. Morgan Healthcare Conference on January 12, 2026 will be posted on the Investor page of its website under the “Events & Presentations” section.
BillionToOne, Inc. (BLLN) filed a Form 4 reporting equity award activity for its Chief Financial Officer. The filing shows stock options with exercise prices of $11.55 and $30.78 covering 175,000 and 75,000 shares, respectively. These options are listed both before and after a reclassification in connection with the company’s initial public offering of Class A common stock.
The filing explains that, under a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically converted into one share of Class A common stock immediately prior to completion of the IPO. The $11.55 options vest over four years, with 25% vested on January 8, 2025 and the rest in monthly installments over three years. The $30.78 options vest in equal monthly installments over four years starting September 15, 2025, contingent on continued service.